Figure 5. EGFR downregulation inhibits cell proliferation, migration, and invasion by downregulating miR-222-5p-targeted CYLD in HepG2 cells. HepG2 cells were treated with sh-NC + mimic-NC, sh-EGFR + mimic-NC, sh-EGFR + miR-222-5p mimic, sh-NC + si-NC, sh-EGFR + si-NC, sh-EGFR + si-CYLD, inhibitor-NC + si-NC, miR-222-5p inhibitor + si-NC, or miR-222-5p inhibitor + si-CYLD. (A) mRNA expression of miR-222-5p and CYLD in HepG2 cells detected by RT-qPCR normalized to U6 and β-actin. (B) Cell viability determined by MTT assay. (C, D) Cell migration determined by Transwell assay (200 ×). (E, F) Cell invasion determined by Transwell assay (200 ×). * p < 0.05 vs. HepG2 treated with sh-NC + mimic-NC, inhibitor-NC + si-NC, or sh-NC + si-NC. # p < 0.05 vs. HepG2 treated with sh-EGFR + mimic-NC, sh-EGFR + si-NC, or miR-222-5p inhibitor + si-NC. Data are expressed as mean ± standard deviation. Data from multiple groups were compared by one-way ANOVA and Tukey’s post hoc test. Data were compared between groups at different time points by repeated measures ANOVA and Bonferroni post hoc test.